⚕ GalenOps field
←

SITE004-0128

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-08-01

AEs
6
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-25 (study day 17); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 31); relationship: not assessed

severe serious assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 54); relationship: not assessed; serious criteria: life-threatening

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 71); relationship: Y

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 72); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 152); relationship: not assessed

Data queries

No data queries.